Drugs / SEP-380135
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07455084 | Mar → Apr 2026 overdue | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07305779 | Mar → May 2025 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07549581 | Nov 2024 → Sep 2025 | bipolar disorder, major depressive disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-15 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Sumitomo Revise License Agreement- Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide - otsuka.co.jp ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEP-380135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07305779 ↗ |
| Known as | 14C-SEP-380135 | “Participants receive a single oral administration of 14C-SEP-380135 on Day 1.” NCT07455084 ↗ |
| Route | Oral | “Oral capsules.” NCT07305779 ↗ |